Eli Lilly and Company (LLY)
Eli Lilly and Company is an American multinational pharmaceutical company. It was founded in 1876 and is headquartered in Indianapolis, Indiana. The company develops, manufactures, and markets a wide range of pharmaceutical products, including prescription drugs and vaccines, for various medical conditions.
Company Info
US5324571083
532457108
Jan 13, 1978
Highlights
$674.60B
$12.27
59.87
1.16
$49.00B
$40.03B
$16.67B
$677.09 - $969.25
$978.82
0.80%
1.77
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Eli Lilly and Company (LLY) returned -4.68% year-to-date (YTD) and -2.72% over the past 12 months. Over the past 10 years, LLY delivered an annualized return of 28.45%, outperforming the S&P 500 benchmark at 10.46%.
LLY
-4.68%
1.89%
-11.36%
-2.72%
37.70%
28.45%
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of LLY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.06% | 13.70% | -10.29% | 8.84% | -18.29% | -4.68% | |||||||
| 2024 | 10.75% | 16.94% | 3.22% | 0.40% | 5.20% | 10.37% | -11.17% | 19.53% | -7.72% | -6.34% | -3.99% | -2.94% | 33.30% |
| 2023 | -5.93% | -9.28% | 10.35% | 15.27% | 8.77% | 9.20% | -3.08% | 22.18% | -3.08% | 3.13% | 6.90% | -1.37% | 60.91% |
| 2022 | -11.16% | 2.28% | 14.57% | 2.01% | 7.66% | 3.44% | 1.68% | -8.33% | 7.34% | 11.98% | 2.76% | -1.41% | 34.24% |
| 2021 | 23.18% | -1.07% | -8.82% | -2.17% | 9.77% | 14.91% | 6.09% | 6.42% | -10.55% | 10.26% | -2.32% | 11.36% | 66.07% |
| 2020 | 6.25% | -9.21% | 9.98% | 11.48% | -0.63% | 7.34% | -8.46% | -0.78% | -0.25% | -11.86% | 12.21% | 15.92% | 31.03% |
| 2019 | 3.58% | 5.94% | 2.75% | -9.80% | -0.38% | -4.44% | -1.66% | 4.27% | -1.01% | 1.90% | 3.58% | 12.00% | 16.14% |
| 2018 | -3.56% | -4.74% | 0.45% | 4.78% | 5.62% | 0.34% | 15.80% | 7.51% | 1.57% | 1.05% | 9.96% | -2.46% | 40.45% |
| 2017 | 4.73% | 8.23% | 1.57% | -2.44% | -2.41% | 3.43% | 0.44% | -1.03% | 5.23% | -4.21% | 3.95% | -0.21% | 17.83% |
| 2016 | -6.12% | -8.34% | 0.01% | 4.89% | 0.00% | 4.96% | 5.26% | -5.60% | 3.23% | -8.00% | -8.51% | 9.58% | -10.37% |
| 2015 | 4.36% | -1.85% | 3.53% | -1.07% | 10.54% | 5.82% | 1.22% | -1.97% | 1.63% | -2.53% | 1.21% | 2.71% | 25.39% |
| 2014 | 5.90% | 11.37% | -1.26% | 0.41% | 2.13% | 3.86% | -1.79% | 4.93% | 2.03% | 2.28% | 3.44% | 1.28% | 39.75% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of LLY is 41, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Eli Lilly and Company (LLY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Eli Lilly and Company provided a 0.74% dividend yield over the last twelve months, with an annual payout of $5.40 per share. The company has been increasing its dividends for 46 consecutive years, earning it the status of a dividend aristocrat.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $5.40 | $5.20 | $4.52 | $3.92 | $3.40 | $2.96 | $2.58 | $2.25 | $2.08 | $2.04 | $2.00 | $1.96 |
Dividend yield | 0.74% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% |
Monthly Dividends
The table displays the monthly dividend distributions for Eli Lilly and Company. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $1.50 | $0.00 | $0.00 | $0.00 | $1.50 | |||||||
| 2024 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $5.20 |
| 2023 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $4.52 |
| 2022 | $0.00 | $0.98 | $0.00 | $0.00 | $0.98 | $0.00 | $0.00 | $0.98 | $0.00 | $0.00 | $0.98 | $0.00 | $3.92 |
| 2021 | $0.00 | $0.85 | $0.00 | $0.00 | $0.85 | $0.00 | $0.00 | $0.85 | $0.00 | $0.00 | $0.85 | $0.00 | $3.40 |
| 2020 | $0.00 | $0.74 | $0.00 | $0.00 | $0.74 | $0.00 | $0.00 | $0.74 | $0.00 | $0.00 | $0.74 | $0.00 | $2.96 |
| 2019 | $0.00 | $0.65 | $0.00 | $0.00 | $0.65 | $0.00 | $0.00 | $0.65 | $0.00 | $0.00 | $0.65 | $0.00 | $2.58 |
| 2018 | $0.00 | $0.56 | $0.00 | $0.00 | $0.56 | $0.00 | $0.00 | $0.56 | $0.00 | $0.00 | $0.56 | $0.00 | $2.25 |
| 2017 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $2.08 |
| 2016 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $2.04 |
| 2015 | $0.00 | $0.50 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.50 | $0.00 | $2.00 |
| 2014 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.49 | $0.00 | $1.96 |
Dividend Yield & Payout
Dividend Yield
Eli Lilly and Company has a dividend yield of 0.74%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Eli Lilly and Company has a payout ratio of 40.70%, which is quite average when compared to the overall market. This suggests that Eli Lilly and Company strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Eli Lilly and Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eli Lilly and Company was 68.27%, occurring on Mar 5, 2009. Recovery took 1428 trading sessions.
The current Eli Lilly and Company drawdown is 23.23%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -68.27% | Aug 9, 2000 | 2154 | Mar 5, 2009 | 1428 | Nov 4, 2014 | 3582 |
| -46.39% | Jan 10, 1992 | 404 | Aug 13, 1993 | 408 | Mar 27, 1995 | 812 |
| -43.28% | Mar 8, 1999 | 254 | Mar 7, 2000 | 80 | Jun 29, 2000 | 334 |
| -40.74% | Sep 15, 1987 | 25 | Oct 19, 1987 | 353 | Mar 13, 1989 | 378 |
| -30.29% | Apr 21, 1981 | 111 | Sep 25, 1981 | 331 | Jan 17, 1983 | 442 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Eli Lilly and Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Eli Lilly and Company, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -3.4%.
Valuation
The Valuation section provides an overview of how Eli Lilly and Company is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for LLY, comparing it with other companies in the Drug Manufacturers - General industry. Currently, LLY has a P/E ratio of 59.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for LLY compared to other companies in the Drug Manufacturers - General industry. LLY currently has a PEG ratio of 1.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LLY relative to other companies in the Drug Manufacturers - General industry. Currently, LLY has a P/S ratio of 13.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LLY in comparison with other companies in the Drug Manufacturers - General industry. Currently, LLY has a P/B value of 44.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |